Global Atherosclerosis Therapeutics Market 2022-2026 The analyst has been monitoring the atherosclerosis therapeutics market and it is poised to grow by $ 3.44 bn during 2022-2026 progressing at a CAGR of 5.66% during the forecast period. Our report on the atherosclerosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing risk factors for atherosclerosis, the availability of advanced diagnostic methods, and the rising prevalence of hypercholesterolemia. The atherosclerosis therapeutics market analysis includes the product segment and geographic landscape.
The atherosclerosis therapeutics market is segmented as below: By Product • Small molecules • Biologics
By Geographical Landscape • North America • Europe • Asia • Rest of World (ROW)
This study identifies the identification of new pathogenic targets as one of the prime reasons driving the atherosclerosis therapeutics market growth during the next few years. Also, identification of new drug targets for atherosclerosis and strong incidence of coronary heart disease (CHD) will lead to sizable demand in the market.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on atherosclerosis therapeutics market covers the following areas: • Atherosclerosis therapeutics market sizing • Atherosclerosis therapeutics market forecast • Atherosclerosis therapeutics market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading atherosclerosis therapeutics market vendors that include Amgen Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Ionis Pharmaceuticals Inc., Merck and Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi SA, Viatris Inc., GlaxoSmithKline Plc, and Pfizer Inc. Also, the atherosclerosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Our reports have been used by over 10K customers, including:
242 pages •
By The Business Research Company
• Jun 2022
Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global coronavirus (COVID-19) current therapy market as it emerges from the COVID 19 shut down. Description: Where...
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Metabotropic Glutamate Receptor 7 - Drugs In Development, 2022’; Metabotropic...
Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target “undruggable” pathways. Technologically advanced platforms are integrated into RNA therapeutics...
120 pages •
By Infiniti Research Limited
• May 2022
Global Neurologic Disorders Therapeutics Market 2022-2026 The analyst has been monitoring the neurologic disorders therapeutics market and it is poised to grow by $ 33.46 bn during 2022-2026, accelerating at a CAGR of 5.44% during the forecast period. Our report on the neurologic disorders therapeutics market provides a...
The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development &...
120 pages •
By Infiniti Research Limited
• Apr 2022
Global Hepatitis B Therapeutics Market 2022-2026 The analyst has been monitoring the hepatitis b therapeutics market and it is poised to grow by $ 471.49 mn during 2022-2026 progressing at a CAGR of 3.29% during the forecast period. Our report on the hepatitis b therapeutics market provides a holistic analysis, market size...
120 pages •
By Infiniti Research Limited
• Mar 2022
Global Oral Cancer Therapeutics Market 2022-2026 The analyst has been monitoring the oral cancer therapeutics market and it is poised to grow by $ 1.14 bn during 2022-2026 decelerating at a CAGR of 7.5% during the forecast period. Our report on the oral cancer therapeutics market provides a holistic analysis, market size...
400 pages •
By The Business Research Company
• Mar 2022
Major players in the orphan drugs market are Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Amgen, Biogen, Bayer, Novartis AG, GlaxoSmithKline plc., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Alexion Pharmaceuticals, Shire, Novo Nordisk, AstraZeneca, Eisai, Daiichi Sankyo, Merck, Teva Pharmaceutical...
400 pages •
By The Business Research Company
• Mar 2022
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC., GlaxoSmithKline (GSK), Novartis AG and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to grow from $0.93 billion in 2021 to $1.21...
Pharmaceutical
Biosimilar
Chronic Disease
Drug Development
Biotechnology
Therapy
World
United Kingdom
United States
Drug Approval
Biosimilar Sales
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.